Evaluation of the anti-angiogenic properties of the new selective alpha(V)beta(3) integrin antagonist RGDechiHCit
Abstract
Integrins are heterodimeric receptors that play a critical role in cell-cell and cell-matrix adhesion processes. Among them, ?V?3 integrin, that recognizes the aminoacidic RGD triad, is reported to be involved in angiogenesis, tissue repair and tumor growth. We have recently synthesized a new and selective ligand of ?V?3 receptor, referred to as RGDechiHCit, that contains a cyclic RGD motif and two echistatin moieties.MethodsThe aim of this study is to evaluate in vitro and in vivo the effects of RGDechiHCit. Therefore, we assessed its properties in cellular (endothelial cells [EC], and vascular smooth muscle cells [VSMC]) and animal models (Wistar Kyoto rats and c57Bl/6 mice) of angiogenesis.ResultsIn EC, but not VSMC, RGDechiHCit inhibits intracellular mitogenic signaling and cell proliferation. Furthermore, RGDechiHCit blocks the ability of EC to form tubes on Matrigel. In vivo, wound healing is delayed in presence of RGDechiHCit. Similarly, Matrigel plugs demonstrate an antiangiogenic effect of RGDechiHCit.ConclusionsOur data indicate the importance of RGDechiHCit in the selective inhibition of endothelial ?V?3 integrin in vitro and in vivo. Such inhibition opens new fields of investigation on the mechanisms of angiogenesis, offering clinical implications for treatment of pathophysiological conditions such as cancer, proliferative retinopathy and inflammatory disease.
Autore Pugliese
Tutti gli autori
-
Santulli G.; Basilicata M.F.; De Simone M.; Del Giudice C.; Anastasio A.; Sorriento D.; Saviano M.; Del Gatto A.; Trimarco B.; Pedone C.; Zaccaro L.; Iaccarino G.
Titolo volume/Rivista
Journal of translational medicine
Anno di pubblicazione
2011
ISSN
1479-5876
ISBN
Non Disponibile
Numero di citazioni Wos
Nessuna citazione
Ultimo Aggiornamento Citazioni
Non Disponibile
Numero di citazioni Scopus
Non Disponibile
Ultimo Aggiornamento Citazioni
Non Disponibile
Settori ERC
Non Disponibile
Codici ASJC
Non Disponibile
Condividi questo sito sui social